Tag: FDA approvals
-
Biosimilars, Generics, and the New Cost-Control Countertrend in Pharmaceuticals
Prescription drug prices have long been a primary concern for patients, payers, and policymakers worldwide. In recent years, the surge of biosimilars and generics has emerged as a leading force in reshaping the economics of the pharmaceutical industry, promising not only reduced costs but also greater competition and accessibility. As of 2025, this movement —